Gout prevalence and predictors of urate-lowering therapy use: Results from a population-based study

Huai Leng Pisaniello, Susan Lester, David Gonzalez-Chica, Nigel Stocks, Marie Longo, Greg R. Sharplin, Eleonora Dal Grande, Tiffany K. Gill, Samuel L. Whittle, Catherine L. Hill

Research output: Contribution to journalArticle

7 Citations (Scopus)

Abstract

Background: Gout has an increasing global prevalence. Underutilization of urate-lowering therapy (ULT) is thought to be common, via both suboptimal dosing and poor medication adherence. The aims of this study were to determine the prevalence of self-reported gout and the key predictors of ULT use in those with gout in a representative population survey in South Australia. Methods: Data were obtained from the Spring 2015 South Australian Health Omnibus Survey, a multilevel, systematic, survey in a representative population sample involving face-to-face interviews (n = 3005). This study analyzed responses from respondents aged ≥ 25 years (n = 2531) about self-reported gout, ULT use, sociodemographic factors, lifestyle factors, and comorbidities, using survey weighting. Univariate and subsequent adjusted logistic regression analyses on self-reported gout were performed. ULT use was divided into three categories (never use, prior use, and current use) and these data were analyzed using a multinomial logistic regression model. Results: Self-reported gout prevalence was 6.8% (95% CI 5.8, 7.9). The mean age of respondents with gout was 64 years (standard deviation 16) and 82% were male. As expected, older age, male gender, lower socioeconomic status (SES), and higher body mass index (BMI) were associated with gout, as were high alcohol consumption, current smoking, other forms of arthritis, and hypertension or hypercholesterolemia medication, after adjustment for sociodemographic variables. Two thirds of respondents with gout reported ULT use (36% current; 29% previous) with only 55% continuing treatment. Predictors of ULT use included male gender, low SES, and concomitant cholesterol-lowering therapy. Respondents with gout with a higher BMI were more likely to remain on ULT. Conclusions: Despite gout being a common, potentially disabling joint disease, only 55% of respondents with gout in this study adhered to ULT. Identification of key predictors of ULT use will provide guidance on prescribing strategy in clinical practice and on the quality of gout care in the community.

LanguageEnglish
Article number143
JournalArthritis Research and Therapy
Volume20
Issue number1
DOIs
Publication statusPublished - 11 Jul 2018
Externally publishedYes

Keywords

  • Gout
  • Population
  • Predictors
  • Prevalence
  • Urate-lowering therapy

ASJC Scopus subject areas

  • Rheumatology
  • Immunology and Allergy
  • Immunology

Cite this

Pisaniello, H. L., Lester, S., Gonzalez-Chica, D., Stocks, N., Longo, M., Sharplin, G. R., ... Hill, C. L. (2018). Gout prevalence and predictors of urate-lowering therapy use: Results from a population-based study. Arthritis Research and Therapy, 20(1), [143]. https://doi.org/10.1186/s13075-018-1633-9
Pisaniello, Huai Leng ; Lester, Susan ; Gonzalez-Chica, David ; Stocks, Nigel ; Longo, Marie ; Sharplin, Greg R. ; Dal Grande, Eleonora ; Gill, Tiffany K. ; Whittle, Samuel L. ; Hill, Catherine L. / Gout prevalence and predictors of urate-lowering therapy use : Results from a population-based study. In: Arthritis Research and Therapy. 2018 ; Vol. 20, No. 1.
@article{587a007e3eda4927a797b941cd192ef1,
title = "Gout prevalence and predictors of urate-lowering therapy use: Results from a population-based study",
abstract = "Background: Gout has an increasing global prevalence. Underutilization of urate-lowering therapy (ULT) is thought to be common, via both suboptimal dosing and poor medication adherence. The aims of this study were to determine the prevalence of self-reported gout and the key predictors of ULT use in those with gout in a representative population survey in South Australia. Methods: Data were obtained from the Spring 2015 South Australian Health Omnibus Survey, a multilevel, systematic, survey in a representative population sample involving face-to-face interviews (n = 3005). This study analyzed responses from respondents aged ≥ 25 years (n = 2531) about self-reported gout, ULT use, sociodemographic factors, lifestyle factors, and comorbidities, using survey weighting. Univariate and subsequent adjusted logistic regression analyses on self-reported gout were performed. ULT use was divided into three categories (never use, prior use, and current use) and these data were analyzed using a multinomial logistic regression model. Results: Self-reported gout prevalence was 6.8{\%} (95{\%} CI 5.8, 7.9). The mean age of respondents with gout was 64 years (standard deviation 16) and 82{\%} were male. As expected, older age, male gender, lower socioeconomic status (SES), and higher body mass index (BMI) were associated with gout, as were high alcohol consumption, current smoking, other forms of arthritis, and hypertension or hypercholesterolemia medication, after adjustment for sociodemographic variables. Two thirds of respondents with gout reported ULT use (36{\%} current; 29{\%} previous) with only 55{\%} continuing treatment. Predictors of ULT use included male gender, low SES, and concomitant cholesterol-lowering therapy. Respondents with gout with a higher BMI were more likely to remain on ULT. Conclusions: Despite gout being a common, potentially disabling joint disease, only 55{\%} of respondents with gout in this study adhered to ULT. Identification of key predictors of ULT use will provide guidance on prescribing strategy in clinical practice and on the quality of gout care in the community.",
keywords = "Gout, Population, Predictors, Prevalence, Urate-lowering therapy",
author = "Pisaniello, {Huai Leng} and Susan Lester and David Gonzalez-Chica and Nigel Stocks and Marie Longo and Sharplin, {Greg R.} and {Dal Grande}, Eleonora and Gill, {Tiffany K.} and Whittle, {Samuel L.} and Hill, {Catherine L.}",
year = "2018",
month = "7",
day = "11",
doi = "10.1186/s13075-018-1633-9",
language = "English",
volume = "20",
journal = "Arthritis Research and Therapy",
issn = "1478-6354",
publisher = "BioMed Central",
number = "1",

}

Pisaniello, HL, Lester, S, Gonzalez-Chica, D, Stocks, N, Longo, M, Sharplin, GR, Dal Grande, E, Gill, TK, Whittle, SL & Hill, CL 2018, 'Gout prevalence and predictors of urate-lowering therapy use: Results from a population-based study', Arthritis Research and Therapy, vol. 20, no. 1, 143. https://doi.org/10.1186/s13075-018-1633-9

Gout prevalence and predictors of urate-lowering therapy use : Results from a population-based study. / Pisaniello, Huai Leng; Lester, Susan; Gonzalez-Chica, David; Stocks, Nigel; Longo, Marie; Sharplin, Greg R.; Dal Grande, Eleonora; Gill, Tiffany K.; Whittle, Samuel L.; Hill, Catherine L.

In: Arthritis Research and Therapy, Vol. 20, No. 1, 143, 11.07.2018.

Research output: Contribution to journalArticle

TY - JOUR

T1 - Gout prevalence and predictors of urate-lowering therapy use

T2 - Arthritis Research and Therapy

AU - Pisaniello, Huai Leng

AU - Lester, Susan

AU - Gonzalez-Chica, David

AU - Stocks, Nigel

AU - Longo, Marie

AU - Sharplin, Greg R.

AU - Dal Grande, Eleonora

AU - Gill, Tiffany K.

AU - Whittle, Samuel L.

AU - Hill, Catherine L.

PY - 2018/7/11

Y1 - 2018/7/11

N2 - Background: Gout has an increasing global prevalence. Underutilization of urate-lowering therapy (ULT) is thought to be common, via both suboptimal dosing and poor medication adherence. The aims of this study were to determine the prevalence of self-reported gout and the key predictors of ULT use in those with gout in a representative population survey in South Australia. Methods: Data were obtained from the Spring 2015 South Australian Health Omnibus Survey, a multilevel, systematic, survey in a representative population sample involving face-to-face interviews (n = 3005). This study analyzed responses from respondents aged ≥ 25 years (n = 2531) about self-reported gout, ULT use, sociodemographic factors, lifestyle factors, and comorbidities, using survey weighting. Univariate and subsequent adjusted logistic regression analyses on self-reported gout were performed. ULT use was divided into three categories (never use, prior use, and current use) and these data were analyzed using a multinomial logistic regression model. Results: Self-reported gout prevalence was 6.8% (95% CI 5.8, 7.9). The mean age of respondents with gout was 64 years (standard deviation 16) and 82% were male. As expected, older age, male gender, lower socioeconomic status (SES), and higher body mass index (BMI) were associated with gout, as were high alcohol consumption, current smoking, other forms of arthritis, and hypertension or hypercholesterolemia medication, after adjustment for sociodemographic variables. Two thirds of respondents with gout reported ULT use (36% current; 29% previous) with only 55% continuing treatment. Predictors of ULT use included male gender, low SES, and concomitant cholesterol-lowering therapy. Respondents with gout with a higher BMI were more likely to remain on ULT. Conclusions: Despite gout being a common, potentially disabling joint disease, only 55% of respondents with gout in this study adhered to ULT. Identification of key predictors of ULT use will provide guidance on prescribing strategy in clinical practice and on the quality of gout care in the community.

AB - Background: Gout has an increasing global prevalence. Underutilization of urate-lowering therapy (ULT) is thought to be common, via both suboptimal dosing and poor medication adherence. The aims of this study were to determine the prevalence of self-reported gout and the key predictors of ULT use in those with gout in a representative population survey in South Australia. Methods: Data were obtained from the Spring 2015 South Australian Health Omnibus Survey, a multilevel, systematic, survey in a representative population sample involving face-to-face interviews (n = 3005). This study analyzed responses from respondents aged ≥ 25 years (n = 2531) about self-reported gout, ULT use, sociodemographic factors, lifestyle factors, and comorbidities, using survey weighting. Univariate and subsequent adjusted logistic regression analyses on self-reported gout were performed. ULT use was divided into three categories (never use, prior use, and current use) and these data were analyzed using a multinomial logistic regression model. Results: Self-reported gout prevalence was 6.8% (95% CI 5.8, 7.9). The mean age of respondents with gout was 64 years (standard deviation 16) and 82% were male. As expected, older age, male gender, lower socioeconomic status (SES), and higher body mass index (BMI) were associated with gout, as were high alcohol consumption, current smoking, other forms of arthritis, and hypertension or hypercholesterolemia medication, after adjustment for sociodemographic variables. Two thirds of respondents with gout reported ULT use (36% current; 29% previous) with only 55% continuing treatment. Predictors of ULT use included male gender, low SES, and concomitant cholesterol-lowering therapy. Respondents with gout with a higher BMI were more likely to remain on ULT. Conclusions: Despite gout being a common, potentially disabling joint disease, only 55% of respondents with gout in this study adhered to ULT. Identification of key predictors of ULT use will provide guidance on prescribing strategy in clinical practice and on the quality of gout care in the community.

KW - Gout

KW - Population

KW - Predictors

KW - Prevalence

KW - Urate-lowering therapy

UR - http://www.scopus.com/inward/record.url?scp=85050035583&partnerID=8YFLogxK

U2 - 10.1186/s13075-018-1633-9

DO - 10.1186/s13075-018-1633-9

M3 - Article

VL - 20

JO - Arthritis Research and Therapy

JF - Arthritis Research and Therapy

SN - 1478-6354

IS - 1

M1 - 143

ER -